Endosc Int Open 2015; 03(06): E605-E609
DOI: 10.1055/s-0034-1393087
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Early clinical experience of the safety and efficacy of EndoClot in the management of non-variceal upper gastrointestinal bleeding

Sabina Beg
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
,
Ibrahim Al-Bakir
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
,
Meha Bhuva
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
,
Jay Patel
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
,
Mark Fullard
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
,
Anthony Leahy
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United Kingdom
› Author Affiliations
Further Information

Publication History

submitted 04 May 2015

accepted after revision 11 August 2015

Publication Date:
27 November 2015 (online)

Background and study aims: EndoClot is a novel topical hemostatic powder approved for use in non-variceal upper gastrointestinal bleeding. This study examines its impact as rescue therapy in the management of gastrointestinal bleeding for which standard endoscopic therapy failed to achieve hemostasis.

Methods: This observational study covered a 24-month period. Data were collated from patients treated with EndoClot for comparison with a cohort of patients managed with standard endoscopic therapy. End points of this study included immediate hemostasis, 30-day rebleed rate, 30-day mortality rate, and adverse events.

Results: Between April 1, 2012, and March 31, 2014, gastroscopic procedures were performed in 1009 patients, of whom 173 required endoscopic therapy. EndoClot was used in 21 patients, with immediate hemostasis achieved in all cases, a 30-day rebleed rate of 4.8 % (95 % confidence interval [95 %CI] – 4.34 % to 3.94 %), and a 30-day mortality rate of 19.0 % (95 %CI 2.29 % – 35.91 %). Despite higher risk bleeds in this cohort of patients, Fisher's exact test demonstrated no significant difference between their 30-day mortality rate (P = 0.51) and rebleed rate (P = 0.31) and those of the patients treated with standard endoscopic hemostatic techniques.

Conclusions: This study demonstrates that EndoClot can be used both safely and effectively in the management of non-variceal upper gastrointestinal bleeding.

 
  • References

  • 1 Hearnshaw SA, Logan RF, Lowe D et al. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut 2010; 59: 1022-1029
  • 2 Hearnshaw SA, Logan RF, Lowe D et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335
  • 3 Rockall TA, Logan RF, Devlin HB et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage, Lancet 1995; 346: 346-350
  • 4 Rockall TA, Logan RF, Devlin HB et al. Influencing the practice and outcome in acute upper gastrointestinal haemorrhage. Steering Committee of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Gut 1997; 41: 606-611
  • 5 NICE. National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding: management. NICE guideline CG141. https://www.nice.org.uk/guidance/cg141/resources [Accessed August 15, 2015; Published June 2012]
  • 6 SIGN. Scottish Intercollegiate Guidelines Network. Management of acute upper and lower gastrointestinal bleeding: a national clinical guideline. SIGN guideline 105. http://www.sign.ac.uk/pdf/sign105.pdf [Accessed August 15, 2015; Published September 2008]
  • 7 Holster IL, Kuipers EJ, Tjwa ETTL. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45: 63-66
  • 8 Vitramed. Revolutionary haemostasis system. EndoClot. www.vitramed.com.au/EndoClot.aspx [Accessed August 15, 2015; Published 2011]
  • 9 Bustamante-Balén M, Plumé G. Role of hemostatic powders in the endoscopic management of gastrointestinal bleeding. World J Gastrointest Pathophysiol 2014; 5: 284-292
  • 10 Weusten B, Bergman JJ. A hemostatic spray: the easy way out for upper gastrointestinal bleeding?. Endoscopy 2011; 43: 343-344
  • 11 Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2: 394–397
  • 12 Changela K, Papafragkakis H, Ofori E et al. Hemostatic powder spray: a new method for managing gastrointestinal bleeding. Therap Adv Gastroenterol 2015; 8: 125-135
  • 13 Sung J, Luo D, Wu C et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
  • 14 Babiuc RD, Purcarea M, Sadagurschi R et al. Use of Hemospray in the treatment of patients with acute UGIB – short review. J Med Life 2013; 6: 117-119
  • 15 Ibrahim M, Lemmers A, Devière J. Novel application of Hemospray to achieve hemostasis in post-variceal banding esophageal ulcers that are actively bleeding. Endoscopy 2014; 46 UCTN E263
  • 16 Curcio G, Granata A, Traina M. Hemospray for multifocal bleeding following ultra-low rectal endoscopic submucosal dissection. Dig Endosc 2014; 26: 606-607
  • 17 Granata A, Curcio G, Barresi L et al. Hemospray rescue treatment of severe refractory bleeding associated with ischemic colitis: a case series. Int J Colorectal Dis 2015 May 6. [Epub ahead of print]
  • 18 Dietrich C, Hochdörffer R, Fuchs ES et al. Successful use of Hemospray to control refractory duodenal diverticular bleeding. Endoscopy 2014; 46 UCTN E605-E606
  • 19 Gungor G, Goktepe MH, Biyik M et al. Efficacy of Ankaferd blood stopper application on non-variceal upper gastrointestinal bleeding. World J Gastrointest Endosc 2012; 4: 556-560